Abstract 32P
Background
Worldwide breast cancer morbidity and mortality was still positioned in the top. Epidemiological data for breast cancer in Bali was not available although is essential for planning health measures. This study aimed to summarise the demographics of breast cancer subjects in Sanglah Genral Hospital from 2012-2019 and emphasize variables that related.
Methods
This is a descriptive study, collecting all breast cancer subjects data from January 2012 to 2019. All data from the cancer registry were analyzed and tabulated. Data were described as count and percentages. Reasoning analysis was done by looking at the counts from year to year. Information for counting age standardized rate was taken in national census data of population in Bali. Literature review if articles were also screened for the filtering out of the data regarding epidemiology of breast cancer in worldwide for comparison.
Results
A total of 1627 cases from 2012 to 2019 were included in this study for analysis. The incidence of breast cancer increase from 187 cases to 364 cases from 2013 to 2016. The age-standardized incidence rate was 84.33 per 100.000 women Balinese population. Most cases were found in advanced stages, stage IIIB (29.38%) and stage IV (22.56%). The most common tumor status found was T4 (49.78%), N1 (41.49%), and 22.5% were found to have metastasis. Lung metastasis dominated all the metastasis cases with the rate of 42.35%. Majority of histopathology subtypes in breast cancer subjects were invasive carcinoma of non special type (NST) (78.8%), followed by invasive lobular carcinoma (12.4%). From 1627 subjects, only 1160 (71.3%) had subtype tested, with luminal B subtype dominated the cases (36.5%).
Conclusions
Geographical and phenotypical variations differ from breast cancer subject epidemiology. Thus, statistical data should be done in each region for a better diagnosis and treatment care.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
504P - A single center report for safety and efficacy of CT-707 in Chinese patients with advanced, anaplastic lymphoma kinase-rearranged non-small cell lung cancer or other tumours
Presenter: Peng Song
Session: Poster display session
Resources:
Abstract
519P - Initial results of lung cancer genomic screening project for individualized medicine in Asia: LC-SCRUM-Asia
Presenter: Chih-Hsi Kuo
Session: Poster display session
Resources:
Abstract
521P - A randomized, phase II study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401)
Presenter: Keisuke Baba
Session: Poster display session
Resources:
Abstract
526P - A phase II study of apatinib in patients with recurrent/metastatic esophageal squamous cell carcinoma (ESCC)
Presenter: Li Chu
Session: Poster display session
Resources:
Abstract
499P - Prevalence of uncommon epidermal growth factor receptor (EGFR) alterations detected by circulating tumour DNA (ctDNA) in non-small cell lung cancer (NSCLC) patients in Hong Kong
Presenter: Oscar Siu Hong Chan
Session: Poster display session
Resources:
Abstract
489P - Overall survival in patients with EGFRm+ NSCLC receiving sequential afatinib and osimertinib: Updated analysis of the GioTag study
Presenter: Maximilian J. Hochmair
Session: Poster display session
Resources:
Abstract
509P - Second-line treatment after first-line vinorelbine in advanced platinum unfit NSCLC patients: An exploratory analysis of randomized Tempo-Lung trial
Presenter: Andrea Camerini
Session: Poster display session
Resources:
Abstract
500P - Clinico-molecular characteristics of Chinese primary non-small cell lung cancer patients with compound EGFR mutations
Presenter: Jianchun Duan
Session: Poster display session
Resources:
Abstract
527P - A multicenter study of NRG1 fusions in Chinese non-small cell lung cancer patients and response to afatinib using next generation sequencing
Presenter: Xingliang Li
Session: Poster display session
Resources:
Abstract
481P - Updated survival outcomes of the phase II study of low starting dose of afatinib as first-line treatment in patients with EGFR mutation-positive non-small cell lung cancer (KTORG1402)
Presenter: Toshihide Yokoyama
Session: Poster display session
Resources:
Abstract